Evans John's Insider Trades & SAST Disclosures
Evans John's most recent trade in Beam Therapeutics Inc was a trade of 155,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 30, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Evans John.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 26.75 per share. | 30 Jan 2025 | 29,800 | 908,859 (1%) | 0% | 26.7 | 797,028 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 27.28 per share. | 30 Jan 2025 | 200 | 908,659 (1%) | 0% | 27.3 | 5,456 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 24.60 per share. | 30 Sep 2024 | 60,000 | 938,659 (1%) | 0% | 24.6 | 1,476,024 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 24.50 per share. | 27 Jun 2024 | 60,000 | 998,343 (2%) | 0% | 24.5 | 1,470,156 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 99,336 | 99,336 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 53,965 | 53,965 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 32.13 per share. | 01 Apr 2024 | 18,102 | 1,058,343 (2%) | 0% | 32.1 | 581,617 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 77,500 | 1,076,445 (2%) | 0% | 0 | Common Stock | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 33.86 per share. | 28 Mar 2024 | 60,000 | 998,262 (2%) | 0% | 33.9 | 2,031,402 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | Evans John | Director, CEO | Sale of securities on an exchange or to another person at price $ 25.33 per share. | 31 Jan 2024 | 60,000 | 1,058,262 (2%) | 0% | 25.3 | 1,519,800 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.09 per share. | 03 Apr 2023 | 6,493 | 1,117,979 (2%) | 0% | 29.1 | 188,904 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 30.31 per share. | 03 Apr 2023 | 5,161 | 1,124,472 (2%) | 0% | 30.3 | 156,430 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 112,500 | 112,500 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 56,250 | 1,115,303 (2%) | 0% | 0 | Common Stock | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.22 per share. | 31 Jan 2023 | 13,850 | 1,129,153 (2%) | 0% | 7.2 | 99,997 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 13,850 | 196,904 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | 31 Jan 2023 | 225 | 1,059,053 (2%) | 0% | 0 | Common Stock | ||
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 46.88 per share. | 31 Oct 2022 | 11,756 | 1,061,429 (2%) | 0% | 46.9 | 551,137 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 46.91 per share. | 31 Oct 2022 | 8,235 | 105,188 (0%) | 0% | 46.9 | 386,339 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 46.19 per share. | 31 Oct 2022 | 7,768 | 1,073,185 (2%) | 0% | 46.2 | 358,819 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 44.92 per share. | 31 Oct 2022 | 7,567 | 1,080,953 (2%) | 0% | 44.9 | 339,944 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 44.93 per share. | 31 Oct 2022 | 5,008 | 117,992 (0%) | 0% | 44.9 | 224,993 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 46.19 per share. | 31 Oct 2022 | 4,569 | 113,423 (0%) | 0% | 46.2 | 211,034 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 47.89 per share. | 31 Oct 2022 | 2,909 | 1,058,520 (2%) | 0% | 47.9 | 139,325 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 47.91 per share. | 31 Oct 2022 | 2,188 | 103,000 (0%) | 0% | 47.9 | 104,836 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 65.82 per share. | 28 Jul 2022 | 15,236 | 1,093,103 (2%) | 0% | 65.8 | 1,002,896 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 65.92 per share. | 28 Jul 2022 | 10,599 | 125,448 (0%) | 0% | 65.9 | 698,673 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 64.87 per share. | 28 Jul 2022 | 10,181 | 1,108,339 (2%) | 0% | 64.9 | 660,429 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 64.88 per share. | 28 Jul 2022 | 6,953 | 136,047 (0%) | 0% | 64.9 | 451,113 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 67.80 per share. | 28 Jul 2022 | 2,848 | 1,088,693 (2%) | 0% | 67.8 | 193,093 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 67.82 per share. | 28 Jul 2022 | 2,247 | 123,000 (0%) | 0% | 67.8 | 152,383 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 66.74 per share. | 28 Jul 2022 | 1,562 | 1,091,541 (2%) | 0% | 66.7 | 104,255 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 66.61 per share. | 28 Jul 2022 | 201 | 125,247 (0%) | 0% | 66.6 | 13,389 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 68.49 per share. | 28 Jul 2022 | 173 | 1,088,520 (2%) | 0% | 68.5 | 11,849 | Common Stock |
| Verve Therapeutics Inc | John Evans | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 28 Apr 2022 | 47,204 | 1,148,520 (2%) | 0% | 1.0 | 48,620 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 47,204 | 237,141 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 37.48 per share. | 28 Apr 2022 | 13,655 | 1,130,965 (2%) | 0% | 37.5 | 511,789 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.22 per share. | 28 Apr 2022 | 12,246 | 1,101,316 (2%) | 0% | 7.2 | 88,416 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 12,246 | 210,754 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 37.84 per share. | 28 Apr 2022 | 7,745 | 148,805 (0%) | 0% | 37.8 | 293,071 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 38.32 per share. | 28 Apr 2022 | 6,842 | 1,124,123 (2%) | 0% | 38.3 | 262,185 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 36.98 per share. | 28 Apr 2022 | 6,450 | 156,550 (0%) | 0% | 37.0 | 238,521 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 39.49 per share. | 28 Apr 2022 | 4,503 | 1,119,620 (2%) | 0% | 39.5 | 177,823 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 36.59 per share. | 28 Apr 2022 | 3,900 | 1,144,620 (2%) | 0% | 36.6 | 142,701 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 38.75 per share. | 28 Apr 2022 | 3,100 | 145,705 (0%) | 0% | 38.8 | 120,125 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 39.73 per share. | 28 Apr 2022 | 2,348 | 143,357 (0%) | 0% | 39.7 | 93,286 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 40.73 per share. | 28 Apr 2022 | 1,100 | 1,118,520 (2%) | 0% | 40.7 | 44,803 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 40.88 per share. | 28 Apr 2022 | 357 | 143,000 (0%) | 0% | 40.9 | 14,594 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 56,250 | 1,095,331 (2%) | 0% | 0 | Common Stock | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 59.11 per share. | 31 Mar 2022 | 6,261 | 1,089,070 (2%) | 0% | 59.1 | 370,088 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 112,500 | 112,500 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 100,000 | 284,345 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 31 Jan 2022 | 100,000 | 1,038,825 (2%) | 0% | 1.0 | 103,000 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 67.44 per share. | 31 Jan 2022 | 13,535 | 942,803 (1%) | 0% | 67.4 | 912,800 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Jan 2022 | 12,000 | 968,825 (1%) | 0% | 0 | Common Stock | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 67.43 per share. | 31 Jan 2022 | 9,408 | 165,672 (0%) | 0% | 67.4 | 634,381 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 66.55 per share. | 31 Jan 2022 | 6,337 | 956,338 (1%) | 0% | 66.5 | 421,727 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 66.48 per share. | 31 Jan 2022 | 4,105 | 175,080 (0%) | 0% | 66.5 | 272,900 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 68.15 per share. | 31 Jan 2022 | 3,978 | 938,825 (1%) | 0% | 68.2 | 271,101 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 65.49 per share. | 31 Jan 2022 | 3,177 | 962,675 (1%) | 0% | 65.5 | 208,062 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 68.16 per share. | 31 Jan 2022 | 2,672 | 163,000 (0%) | 0% | 68.2 | 182,124 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 64.47 per share. | 31 Jan 2022 | 2,172 | 965,852 (1%) | 0% | 64.5 | 140,029 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 65.55 per share. | 31 Jan 2022 | 1,900 | 179,185 (0%) | 0% | 65.6 | 124,545 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 64.46 per share. | 31 Jan 2022 | 1,615 | 181,085 (0%) | 0% | 64.5 | 104,103 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 63.79 per share. | 31 Jan 2022 | 801 | 968,024 (1%) | 0% | 63.8 | 51,096 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 63.45 per share. | 31 Jan 2022 | 300 | 182,700 (0%) | 0% | 63.5 | 19,035 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2021 | 27,700 | 331,645 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 06 Oct 2021 | 27,700 | 1,061,225 (2%) | 0% | 1.0 | 28,531 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 83.47 per share. | 06 Oct 2021 | 13,406 | 1,044,670 (2%) | 0% | 83.5 | 1,118,999 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 84.45 per share. | 06 Oct 2021 | 10,444 | 1,034,226 (2%) | 0% | 84.5 | 881,996 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 83.49 per share. | 06 Oct 2021 | 9,863 | 190,966 (0%) | 0% | 83.5 | 823,462 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 84.45 per share. | 06 Oct 2021 | 7,566 | 183,400 (0%) | 0% | 84.5 | 638,949 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 82.72 per share. | 06 Oct 2021 | 3,149 | 1,058,076 (2%) | 0% | 82.7 | 260,485 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 82.71 per share. | 06 Oct 2021 | 2,171 | 200,829 (0%) | 0% | 82.7 | 179,563 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 85.19 per share. | 06 Oct 2021 | 701 | 1,033,525 (2%) | 0% | 85.2 | 59,718 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 85.24 per share. | 06 Oct 2021 | 400 | 183,000 (0%) | 0% | 85.2 | 34,096 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 12,000 | 359,345 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 19 Aug 2021 | 12,000 | 1,033,525 (2%) | 0% | 1.0 | 12,360 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 99.53 per share. | 19 Aug 2021 | 9,704 | 208,756 (0%) | 0% | 99.5 | 965,839 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 100.35 per share. | 19 Aug 2021 | 5,456 | 203,300 (0%) | 0% | 100.4 | 547,510 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 98.74 per share. | 19 Aug 2021 | 3,140 | 218,460 (0%) | 0% | 98.7 | 310,044 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 97.50 per share. | 19 Aug 2021 | 1,000 | 221,600 (0%) | 0% | 97.5 | 97,500 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 96.38 per share. | 19 Aug 2021 | 400 | 222,600 (0%) | 0% | 96.4 | 38,552 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 101.00 per share. | 19 Aug 2021 | 300 | 203,000 (0%) | 0% | 101 | 30,300 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2021 | 25,000 | 371,345 | - | - | Stock Option (Right to Buy | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 07 Jul 2021 | 25,000 | 1,046,525 (2%) | 0% | 1.0 | 25,750 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 109.58 per share. | 07 Jul 2021 | 4,800 | 1,031,213 (2%) | 0% | 109.6 | 525,984 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 110.54 per share. | 07 Jul 2021 | 3,982 | 1,027,231 (2%) | 0% | 110.5 | 440,170 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 111.51 per share. | 07 Jul 2021 | 3,456 | 1,023,775 (2%) | 0% | 111.5 | 385,379 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 103.52 per share. | 07 Jul 2021 | 2,864 | 1,040,616 (2%) | 0% | 103.5 | 296,481 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 101.27 per share. | 07 Jul 2021 | 2,300 | 1,043,580 (2%) | 0% | 101.3 | 232,921 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 112.62 per share. | 07 Jul 2021 | 2,250 | 1,021,525 (2%) | 0% | 112.6 | 253,395 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 105.44 per share. | 07 Jul 2021 | 1,800 | 1,037,480 (2%) | 0% | 105.4 | 189,792 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 104.40 per share. | 07 Jul 2021 | 1,336 | 1,039,280 (2%) | 0% | 104.4 | 139,478 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 108.65 per share. | 07 Jul 2021 | 800 | 1,036,013 (2%) | 0% | 108.7 | 86,920 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 100.69 per share. | 07 Jul 2021 | 645 | 1,045,880 (2%) | 0% | 100.7 | 64,945 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 106.48 per share. | 07 Jul 2021 | 500 | 1,036,980 (2%) | 0% | 106.5 | 53,240 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 107.31 per share. | 07 Jul 2021 | 167 | 1,036,813 (2%) | 0% | 107.3 | 17,921 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges